Argo Signs $4.2 Billion Agreement Selling Four RNA Candidates to Novartis

Shanghai Argo Biopharma entered two agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. In the first agreement, Argo granted Novartis exclusive global licenses to develop and commercialize a Phase 1 stage program. In addition, Argo will perform discovery and optimization on two Novartis-chosen cardiovascular targets, with Novartis owning an option to acquire a global license. In the second agreement, Argo granted Novartis an exclusive ex-Greater China license to a Phase I/IIa clinical-stage program for a cardiovascular therapy. Based on its cutting-edge RNAi platform, the assets offer promising efficacy and durability according to Argo. More details....

Share this with colleagues: